Literature DB >> 17210773

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.

David M Livermore1, Marina Warner, Shazad Mushtaq, Sarah North, Neil Woodford.   

Abstract

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17210773      PMCID： PMC1803128          DOI： 10.1128/AAC.01347-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS).

Authors:  A P Johnson; H M Aucken; S Cavendish; M Ganner; M C Wale; M Warner; D M Livermore; B D Cookson
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

2.  Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci.

Authors:  Alistair Sinclair; Catherine Arnold; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 3.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

4.  In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Barbara D Foleno; Darren Abbanat; Raul M Goldschmidt; Robert K Flamm; Steve D Paget; Glenda C Webb; Ellyn Wira; Mark J Macielag; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

5.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.

Authors:  Alexander J O'Neill; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

Review 7.  Efficacy of linezolid versus comparator therapies in Gram-positive infections.

Authors:  Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

Review 8.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

9.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

10.  Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.

Authors:  Rosy Reynolds; Nicola Potz; Melissa Colman; Andrea Williams; David Livermore; Alasdair MacGowan
Journal:  J Antimicrob Chemother       Date:  2004-05-05       Impact factor: 5.790
  10 in total
  13 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

3.  Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.

Authors:  Zohar Eyal; Donna Matzov; Miri Krupkin; Itai Wekselman; Susanne Paukner; Ella Zimmerman; Haim Rozenberg; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-13       Impact factor: 11.205

4.  Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis.

Authors:  Lorena Diaz; Pattarachai Kiratisin; Rodrigo E Mendes; Diana Panesso; Kavindra V Singh; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

5.  Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors:  Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 6.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

7.  Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Stephan Schmidt; Sreedharan Nair Sabarinath; April Barbour; Darren Abbanat; Prasarn Manitpisitkul; Sue Sha; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

8.  Polyphyletic emergence of linezolid-resistant staphylococci in the United States.

Authors:  Agnes Wong; Shilpa P Reddy; Davida S Smyth; Maria E Aguero-Rosenfeld; George Sakoulas; D Ashley Robinson
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

9.  In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Jamese J Hilliard; Jeffrey Fernandez; John Melton; Mark J Macielag; Raul Goldschmidt; Karen Bush; Darren Abbanat
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

10.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.